Skip to main content

Abbott Laboratories company profile

  • ABT · NYSE
  • Pharmaceuticals
  • Health Care Equipment
  • S&P 500
$108.52+1.18%Close 13 Nov 2026 · Market value $187.6B

About Abbott Laboratories

Abbott Laboratories is an Illinois corporation engaged in the discovery, development, manufacture, and sale of a broad line of healthcare products. Its operations are organized into established pharmaceutical products, diagnostic products, nutritional products, and medical devices. The established pharmaceutical segment includes branded generic pharmaceuticals, largely marketed outside the United States in emerging markets, and sells to wholesalers, distributors, government agencies, healthcare facilities, and pharmacies. The diagnostic segment sells laboratory, point-of-care, and rapid diagnostic systems and tests to blood banks, hospitals, commercial laboratories, and clinics. The nutritional segment offers infant formula, adult and pediatric nutritional products, and enteral feeding products to consumers and institutions. The medical devices segment provides cardiovascular, diabetes care, and neuromodulation products to hospitals, physicians, and consumers. Abbott operates worldwide and has employees in more than 160 countries.

A summary of the business section of the company's latest annual report, filed 20 Feb 2026.

Company facts

TickerABT · NYSE
SectorPharmaceuticals
IndustryHealth Care Equipment
IndexS&P 500
Fiscal year ends31 December
Reporting currencyUSD
CIK1800
Latest annual report10-K, filed 20 Feb 2026

Officers and directors

NameRoleShares ownedLatest Form 4
D. J. StarksDirector6.7MOpen-market purchase, 27 Apr 2026
H. L. AllenEXECUTIVE VICE PRESIDENT, GC192KShares withheld for tax, 28 Feb 2025
L. D. EarnhardtEVP AND GROUP PRESIDENT71.9KShares withheld for tax, 27 Feb 2026
C. J. ScogginsEXECUTIVE VICE PRESIDENT63.6KShares withheld for tax, 27 Feb 2026
P. P. BoudreauEVP AND CFO51.0KShares withheld for tax, 1 Sep 2026
R. J. AlpernDirector40.8KGrant or award, 25 Apr 2025
N. McKinstryDirector38.7KGrant or award, 24 Apr 2026
S. E. BlountDirector34.1KGrant or award, 24 Apr 2026
J. G. StrattonDirector19.0KOpen-market purchase, 7 May 2026
M. A. KumbierDirector15.7KGrant or award, 24 Apr 2026
D. W. McDewDirector10.4KGrant or award, 24 Apr 2026
M. F. RomanDirector8.5KGrant or award, 24 Apr 2026
C. Babineaux-FontenotDirector5.3KGrant or award, 24 Apr 2026
M. G. O'GradyDirector5.3KGrant or award, 24 Apr 2026
Moreland Mary KEXECUTIVE VICE PRESIDENT—Open-market sale, 5 Nov 2026
Conroy Kevin TDirector—Shares withheld for tax, 23 Sep 2026
MCCOY JOHN A. JR.VICE PRESIDENT AND CONTROLLER—Open-market sale, 2 Sep 2026
Ford Robert BCHAIRMAN AND CEO · Director—Option exercise, 25 Aug 2026
Morrone Louis H.EXECUTIVE VICE PRESIDENT—Code I, 12 Aug 2026
Cushman Elizabeth C.EVP, GC AND SECRETARY—Shares withheld for tax, 27 Jun 2026

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

ABT in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.